| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| IMTXImmatics N.V. | 1.33B | 9.92 | 70.86 | 188.6% | -136.72% | -27.81% | 0.03 | |
| CTMXCytomX Therapeutics, Inc. | 720.1M | 4.25 | 11.18 | 36.45% | 24.66% | 26.09% | ||
| IOVAIovance Biotherapeutics, Inc. | 881.27M | 2.22 | -1.73 | 136.99% | -158.78% | -56.62% | 0.08 | |
| REPLReplimune Group, Inc. | 572.64M | 7.30 | -2.38 | -117.82% | 0.18 | |||
| NKTRNektar Therapeutics | 719.28M | 35.36 | -4.07 | 9.22% | -192.87% | -141.9% | 1.69 | |
| IMNMImmunome, Inc. | 2.52B | 22.85 | -4.57 | -35.5% | -23.01% | -84.4% | 0.03 | |
| IBRXImmunityBio, Inc. | 3.89B | 3.95 | -6.37 | 22.71% | -422.28% | |||
| NRIXNurix Therapeutics, Inc. | 1.91B | 18.86 | -6.55 | -29.15% | -292.5% | -65.76% | 0.05 |
| Jun 2015 | Jun 2016 | Jun 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 510.18M | 546.95M | 558.52M | 8.18M | 995K | 17.9M | 9.73M | 24.99M | 0 | 0 |
| Revenue Growth % | 0.02% | 0.07% | 0.02% | -0.99% | -0.88% | 16.99% | -0.46% | 1.57% | -1% | - |
| Cost of Goods Sold | 395.48M | 411.52M | 5K | 80K | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 0.78% | 0.75% | 0% | 0.01% | - | - | - | - | - | - |
| Gross Profit | 114.7M | 135.43M | 558.52M | 8.1M | 995K | 17.9M | 9.73M | 24.99M | 0 | 0 |
| Gross Margin % | 0.22% | 0.25% | 1% | 0.99% | 1% | 1% | 1% | 1% | - | - |
| Gross Profit Growth % | 0.17% | 0.18% | 3.12% | -0.99% | -0.88% | 16.99% | -0.46% | 1.57% | -1% | - |
| Operating Expenses | 70.43M | 1K | 18.88M | 23.14M | 32.38M | 57.09M | 71.16M | 97.54M | 152.04M | 127.61M |
| OpEx % of Revenue | 0.14% | 0% | 0.03% | 2.83% | 32.55% | 3.19% | 7.31% | 3.9% | - | - |
| Selling, General & Admin | 65.21M | 1K | 2.04M | 8.43M | 8.69M | 22.76M | 22.22M | 26.3M | 26.53M | 28.29M |
| SG&A % of Revenue | 0.13% | 0% | 0% | 1.03% | 8.74% | 1.27% | 2.28% | 1.05% | - | - |
| Research & Development | 5.22M | 5.94M | 16.84M | 14.72M | 23.69M | 34.33M | 48.94M | 71.25M | 106.04M | 99.32M |
| R&D % of Revenue | 0.01% | 0.01% | 0.03% | 1.8% | 23.81% | 1.92% | 5.03% | 2.85% | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 19.46M | 0 |
| Operating Income | 44.27M | -1K | -18.88M | -14.96M | -31.39M | -39.19M | -61.43M | -72.55M | -152.04M | -127.61M |
| Operating Margin % | 0.09% | -0% | -0.03% | -1.83% | -31.55% | -2.19% | -6.31% | -2.9% | - | - |
| Operating Income Growth % | 0.29% | -1% | -18881% | 0.21% | -1.1% | -0.25% | -0.57% | -0.18% | -1.1% | 0.16% |
| EBITDA | 52.36M | 11.85M | -18.88M | -14.88M | -30.15M | -37.24M | -59.9M | -67.54M | -145.94M | -121.15M |
| EBITDA Margin % | 0.1% | 0.02% | -0.03% | -1.82% | -30.3% | -2.08% | -6.16% | -2.7% | - | - |
| EBITDA Growth % | 0.27% | -0.77% | -2.59% | 0.21% | -1.03% | -0.24% | -0.61% | -0.13% | -1.16% | 0.17% |
| D&A (Non-Cash Add-back) | 8.09M | 11.85M | 5K | 80K | 1.24M | 1.95M | 1.54M | 5.01M | 6.1M | 6.47M |
| EBIT | 46.77M | -1K | -33.78M | -14.96M | -28.12M | -39.36M | -61.95M | -69.71M | -142.63M | -117.12M |
| Net Interest Income | 0 | 0 | 0 | 543K | 938K | 651K | -85K | 3.68M | 9.95M | 10.71M |
| Interest Income | 0 | 0 | 0 | 543K | 938K | 785K | 91K | 3.76M | 9.95M | 10.71M |
| Interest Expense | 2.1M | 3.95M | 7M | 0 | 0 | 134K | 176K | 80K | 0 | 4K |
| Other Income/Expense | 402K | 0 | -14.9M | 5.08M | 3.27M | -302K | -691K | 2.76M | 9.38M | 10.49M |
| Pretax Income | 44.67M | -1K | -33.78M | -9.89M | -28.12M | -39.49M | -62.12M | -69.79M | -142.66M | -117.12M |
| Pretax Margin % | 0.09% | -0% | -0.06% | -1.21% | -28.26% | -2.21% | -6.38% | -2.79% | - | - |
| Income Tax | 15.67M | 0 | 0 | -589K | 19K | -2.81M | -125K | 0 | 0 | 0 |
| Effective Tax Rate % | 0.65% | 1% | 1% | 0.94% | 1% | 0.93% | 1% | 1% | 1% | 1% |
| Net Income | 29M | -1K | -33.78M | -9.3M | -28.14M | -36.68M | -62M | -69.79M | -142.66M | -117.12M |
| Net Margin % | 0.06% | -0% | -0.06% | -1.14% | -28.28% | -2.05% | -6.37% | -2.79% | - | - |
| Net Income Growth % | 0.3% | -1% | -33777% | 0.72% | -2.03% | -0.3% | -0.69% | -0.13% | -1.04% | 0.18% |
| Net Income (Continuing) | 29M | -1K | -33.78M | -9.3M | -28.14M | -36.68M | -62M | -69.79M | -142.66M | -117.12M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 1.16 | 0.00 | -1.25 | -0.31 | -1.52 | -5.01 | -2.00 | -1.70 | -3.31 | -1.33 |
| EPS Growth % | 0.25% | -1% | - | 0.75% | -3.9% | -2.3% | 0.6% | 0.15% | -0.95% | 0.6% |
| EPS (Basic) | 1.18 | 0.00 | -1.26 | -0.31 | -1.52 | -5.01 | -2.00 | -1.70 | -3.31 | -1.33 |
| Diluted Shares Outstanding | 24.99M | 28.05M | 26.97M | 29.8M | 18.56M | 7.32M | 30.95M | 41.08M | 43.04M | 87.87M |
| Basic Shares Outstanding | 24.5M | 28.05M | 26.77M | 29.8M | 18.56M | 7.32M | 30.95M | 41.08M | 43.04M | 87.87M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Jun 2015 | Jun 2016 | Jun 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 310.31M | 352.66M | 54.23M | 109.53M | 64.19M | 100.34M | 282.44M | 261.04M | 162.27M | 180.14M |
| Cash & Short-Term Investments | 37.44M | 67.71M | 53.35M | 108.03M | 62.4M | 94.61M | 277.54M | 257.66M | 159.71M | 176.3M |
| Cash Only | 34.02M | 66.83M | 53.35M | 7.04M | 10.61M | 84.33M | 277.54M | 257.66M | 159.71M | 56.49M |
| Short-Term Investments | 3.42M | 881K | 0 | 100.99M | 51.79M | 10.28M | 0 | 0 | 0 | 119.81M |
| Accounts Receivable | 161.52M | 167.61M | 0 | 0 | 935K | 2.73M | 214K | 435K | 0 | 0 |
| Days Sales Outstanding | 115.56 | 111.85 | - | - | 342.99 | 55.68 | 8.03 | 6.35 | - | - |
| Inventory | 95.6M | 98.11M | 136.39M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | 88.23 | 87.02 | 1000K | - | - | - | - | - | - | - |
| Other Current Assets | 15.76M | 19.23M | 84K | 15K | 179K | 363K | 2K | 336K | 457K | 474K |
| Total Non-Current Assets | 179.46M | 188.12M | 968K | 405K | 17.4M | 53.5M | 56.5M | 69.65M | 45.02M | 40.08M |
| Property, Plant & Equipment | 10.46M | 10.04M | 39K | 321K | 2.12M | 25.86M | 35M | 48.98M | 44.2M | 36.75M |
| Fixed Asset Turnover | 48.79x | 54.46x | 14321.13x | 25.49x | 0.47x | 0.69x | 0.28x | 0.51x | - | - |
| Goodwill | 67.87M | 67.87M | 236.97M | 0 | 0 | 20.09M | 19.46M | 19.46M | 0 | 0 |
| Intangible Assets | 79M | 79.07M | 285.08M | 0 | 0 | 1.19M | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | -541.5M | 84K | 10.59M | 4.53M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 12.17M | 13.08M | 929K | 0 | 4.69M | 1.84M | 2.04M | 1.21M | 822K | 3.33M |
| Total Assets | 489.77M | 540.78M | 55.19M | 109.94M | 81.59M | 153.84M | 338.94M | 330.69M | 207.29M | 220.22M |
| Asset Turnover | 1.04x | 1.01x | 10.12x | 0.07x | 0.01x | 0.12x | 0.03x | 0.08x | - | - |
| Asset Growth % | 0.05% | 0.1% | -0.9% | 0.99% | -0.26% | 0.89% | 1.2% | -0.02% | -0.37% | 0.06% |
| Total Current Liabilities | 125M | 98.91M | 5.5M | 5.72M | 14.87M | 22.48M | 16.32M | 19.71M | 19.29M | 19.39M |
| Accounts Payable | 54.96M | 0 | 1.51M | 538K | 1.05M | 1.55M | 3.26M | 4.4M | 2.63M | 4.83M |
| Days Payables Outstanding | 50.73 | - | 110.59K | 2.45K | - | - | - | - | - | - |
| Short-Term Debt | 10.2M | 197K | 14.47M | 0 | 0 | 1.22M | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 238K | 0 | 1000K | 1000K | 1000K | 0 | 0 | 0 |
| Other Current Liabilities | 57.79M | 49.43M | -10.72M | 3.99M | 1.36M | 1.9M | 4.02M | 5.7M | 6.93M | 7.11M |
| Current Ratio | 2.48x | 3.57x | 9.86x | 19.16x | 4.32x | 4.46x | 17.31x | 13.25x | 8.41x | 9.29x |
| Quick Ratio | 1.72x | 2.57x | -14.93x | 19.16x | 4.32x | 4.46x | 17.31x | 13.25x | 8.41x | 9.29x |
| Cash Conversion Cycle | 153.06 | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 107.57M | 134.08M | 407.97M | 19K | 127.09M | 21.53M | 19.49M | 18.64M | 17.83M | 14.22M |
| Long-Term Debt | 99.96M | 118.59M | 339.2M | 3.11M | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 20.42M | 19.38M | 18.53M | 17.7M | 14.1M |
| Deferred Tax Liabilities | 66K | 9.14M | 7.33M | 0 | 0 | 125K | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 7.54M | 6.34M | -346.52M | -3.09M | 116.2M | 980K | 115K | 114K | 130K | 116K |
| Total Liabilities | 235.56M | 236.34M | 5.5M | 5.74M | 141.95M | 44.01M | 35.81M | 38.35M | 37.12M | 33.61M |
| Total Debt | 110.16M | 118.79M | 353.67M | 3.11M | 0 | 21.64M | 20.94M | 21.02M | 20.92M | 17.23M |
| Net Debt | 76.14M | 51.96M | 300.32M | -3.93M | -10.61M | -62.69M | -256.6M | -236.63M | -138.79M | -39.26M |
| Debt / Equity | 0.43x | 0.39x | 7.12x | 0.03x | - | 0.20x | 0.07x | 0.07x | 0.12x | 0.09x |
| Debt / EBITDA | 2.10x | 10.03x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | 1.45x | 4.39x | - | - | - | - | - | - | - | - |
| Interest Coverage | 21.08x | -0.00x | -2.70x | - | - | -292.47x | -349.05x | -906.89x | - | -31903.75x |
| Total Equity | 254.21M | 304.44M | 49.69M | 104.2M | -60.37M | 109.83M | 303.13M | 292.34M | 170.18M | 186.61M |
| Equity Growth % | 0.09% | 0.2% | -0.84% | 1.1% | -1.58% | 2.82% | 1.76% | -0.04% | -0.42% | 0.1% |
| Book Value per Share | 10.17 | 10.85 | 1.84 | 3.50 | -3.25 | 15.00 | 9.79 | 7.12 | 3.95 | 2.12 |
| Total Shareholders' Equity | 254.21M | 304.44M | 49.69M | 104.2M | -60.37M | 109.83M | 303.13M | 292.34M | 170.18M | 186.61M |
| Common Stock | 292K | 296K | 1K | 3K | 0 | 2K | 4K | 4K | 4K | 8K |
| Retained Earnings | 167.21M | 194.8M | -33.78M | -71.39M | -69.65M | -106.33M | -168.32M | -238.11M | -380.77M | -497.89M |
| Treasury Stock | 0 | 0 | 0 | 129.56M | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -7.1M | -6.33M | -5.11M | -41K | 23K | 24K | 0 | 0 | 0 | 16K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Jun 2015 | Jun 2016 | Jun 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 25.06M | 8.34M | -11.55M | -18.18M | -27.88M | -41.55M | -51.05M | -44.77M | -93.72M | -92.38M |
| Operating CF Margin % | 0.05% | 0.02% | -0.02% | -2.22% | -28.02% | -2.32% | -5.25% | -1.79% | - | - |
| Operating CF Growth % | -0.02% | -0.67% | -2.38% | -0.57% | -0.53% | -0.49% | -0.23% | 0.12% | -1.09% | 0.01% |
| Net Income | 29M | 33.48M | -33.78M | -9.3M | -28.14M | -36.68M | -62M | -69.79M | -142.66M | -117.12M |
| Depreciation & Amortization | 8.09M | 11.85M | 5K | 1.22M | 1.24M | 1.23M | 1.54M | 2.58M | 6.1M | 6.47M |
| Stock-Based Compensation | 0 | 0 | 470K | 2.48M | 1.18M | 5.26M | 12.51M | 17.13M | 20.26M | 22.23M |
| Deferred Taxes | 3.08M | 1.87M | 18K | 0 | 0 | 3.2M | 1.23M | 0 | 0 | 0 |
| Other Non-Cash Items | -47.71M | -70.88M | 16.57M | -4.54M | -2.5M | -1.04M | 1.72M | 2.58M | 22.33M | 1.57M |
| Working Capital Changes | 29.44M | 27.48M | 4.26M | -8.05M | 341K | -13.52M | -6.06M | 2.74M | 252K | -5.53M |
| Change in Receivables | -19.4M | -44.18M | -6.15M | 0 | 0 | 0 | -30K | 185K | 0 | 0 |
| Change in Inventory | -7.76M | -229K | -2.49M | 0 | 0 | 0 | 2.01M | 0 | 0 | 0 |
| Change in Payables | 5.22M | 8.13M | 1.39M | -282K | 527K | -814K | 1.14M | 1.71M | -1.68M | 1.11M |
| Cash from Investing | -85.92M | -8.97M | -44K | -16.06M | -47.93M | 115.22M | -2.8M | -16.78M | -4.46M | -119.24M |
| Capital Expenditures | -1.15M | -617K | -44K | -876K | -1.07M | -990K | -13.05M | -16.78M | -4.46M | -1.12M |
| CapEx % of Revenue | 0% | 0% | 0% | 0.11% | 1.08% | 0.06% | 1.34% | 0.67% | - | - |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 4.08M | -8.32M | -6.71M | -7.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 70.53M | 0 | 64.95M | 11.05M | 76.94M | 303K | 242.69M | 41.51M | 236K | 111.31M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 70.53M | 0 | 0 | 221K | 30K | -157K | 4.56M | -1.85M | -150K | 389K |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | 23.91M | 7.73M | -11.6M | -19.06M | -28.95M | -42.54M | -64.1M | -61.55M | -98.18M | -93.5M |
| FCF Margin % | 0.05% | 0.01% | -0.02% | -2.33% | -29.1% | -2.38% | -6.59% | -2.46% | - | - |
| FCF Growth % | -0.02% | -0.68% | -2.5% | -0.64% | -0.52% | -0.47% | -0.51% | 0.04% | -0.6% | 0.05% |
| FCF per Share | 0.96 | 0.28 | -0.43 | -0.64 | -1.56 | -5.81 | -2.07 | -1.50 | -2.28 | -1.06 |
| FCF Conversion (FCF/Net Income) | 0.86x | -8343.00x | 0.34x | 1.96x | 0.99x | 1.13x | 0.82x | 0.64x | 0.66x | 0.79x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 5.11M | 1K | 3K | 43K | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 11.89% | -0% | -19.08% | -12.08% | -128.37% | -148.31% | -30.03% | -23.44% | -61.69% | -65.65% |
| Return on Invested Capital (ROIC) | 10.6% | -0% | -4.01% | -4.98% | -160.68% | -62.36% | -98.38% | -106.45% | -261.85% | -107.1% |
| Gross Margin | 22.48% | 24.76% | 100% | 99.02% | 100% | 100% | 100% | 100% | - | - |
| Net Margin | 5.68% | -0% | -6.05% | -113.67% | -2827.94% | -204.87% | -637.19% | -279.27% | - | - |
| Debt / Equity | 0.43x | 0.39x | 7.12x | 0.03x | - | 0.20x | 0.07x | 0.07x | 0.12x | 0.09x |
| Interest Coverage | 21.08x | -0.00x | -2.70x | - | - | -292.47x | -349.05x | -906.89x | - | -31903.75x |
| FCF Conversion | 0.86x | -8343.00x | 0.34x | 1.96x | 0.99x | 1.13x | 0.82x | 0.64x | 0.66x | 0.79x |
| Revenue Growth | 2.1% | 7.21% | 2.12% | -98.54% | -87.84% | 1699.3% | -45.65% | 156.83% | -100% | - |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|
| Human Health | 105.25M | 129.67M | 160.22M | 225.26M | 228.03M | 315.39M |
| Human Health Growth | - | 23.20% | 23.56% | 40.60% | 1.23% | 38.31% |
| Performance Chemicals | 176.14M | 185.17M | 173.54M | 172.39M | 169.48M | 165.48M |
| Performance Chemicals Growth | - | 5.13% | -6.28% | -0.66% | -1.69% | -2.36% |
| Pharmaceutical Ingredients | 163M | 184.85M | 176.43M | 149.3M | 161.01M | 157.44M |
| Pharmaceutical Ingredients Growth | - | 13.41% | -4.56% | -15.38% | 7.85% | -2.21% |
| 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | |
|---|---|---|---|---|---|---|
| UNITED STATES | - | - | - | - | - | 483.68M |
| UNITED STATES Growth | - | - | - | - | - | - |
| GERMANY | - | - | 84.02M | 69.89M | 76.67M | 79.11M |
| GERMANY Growth | - | - | - | -16.82% | 9.70% | 3.18% |
| FRANCE | - | - | 29.41M | 27.98M | 30.18M | 35.8M |
| FRANCE Growth | - | - | - | -4.88% | 7.87% | 18.62% |
| Asia Pacific | 25.28M | 28.4M | 26.16M | 27.33M | 34.58M | 29.79M |
| Asia Pacific Growth | - | 12.36% | -7.90% | 4.47% | 26.54% | -13.85% |
| NETHERLANDS | - | - | 14.87M | 14.66M | 16.22M | 9.95M |
| NETHERLANDS Growth | - | - | - | -1.43% | 10.65% | -38.65% |
| United States | 289.63M | 326.25M | - | - | - | - |
| United States Growth | - | 12.64% | - | - | - | - |
| Germany | 82.6M | 92.05M | - | - | - | - |
| Germany Growth | - | 11.44% | - | - | - | - |
| France | 33.14M | 38.48M | - | - | - | - |
| France Growth | - | 16.09% | - | - | - | - |
| Netherlands | 13.74M | 14.51M | - | - | - | - |
| Netherlands Growth | - | 5.64% | - | - | - | - |
Adicet Bio, Inc. (ACET) grew revenue by 0.0% over the past year. Growth has been modest.
Adicet Bio, Inc. (ACET) reported a net loss of $115.0M for fiscal year 2024.
Adicet Bio, Inc. (ACET) has a return on equity (ROE) of -65.7%. Negative ROE indicates the company is unprofitable.
Adicet Bio, Inc. (ACET) had negative free cash flow of $100.4M in fiscal year 2024, likely due to heavy capital investments.